FDA
-
-
-
-
-
-
-
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease
-
-
-
-
-
-
-
Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences
-
-
-
-
-
-
-
Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update
-
-
-
-
-
-
-
Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
-
-
-
-
-
-
-
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
-
-
-
-
-
-
-
Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update
-
-
-
-
-
-
-
Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
-
327,903 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

